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AbstrACt
Objective To develop and validate a prognostic model and 
a simple model to predict death due to bleeding in trauma 
patients.
Design Cross-sectional study with multivariable logistic 
regression using data from two large trauma cohorts.
setting 274 hospitals from 40 countries in the 
Clinical Randomisation of Anti-fibrinolytic in Significant 
Haemorrhage (CRASH-2) trial and 24 hospitals in the 
Northern French Alps Trauma registry.
Participants 13 485 trauma patients in the CRASH-2 trial 
and 9945 patients in the Northern French Alps Trauma 
registry who were admitted to hospital within 3 hours of 
injury.
Main outcome measure In-hospital death due to 
bleeding within 28 days.
results There were 815 (6%) deaths from bleeding in the 
CRASH-2 trial and 102 (1%) in the Northern French Alps 
Trauma registry. The full model included age, systolic blood 
pressure (SBP), Glasgow Coma Scale (GCS), heart rate, 
respiratory rate and type of injury (penetrating). The simple 
model included age, SBP and GCS. In a cross-validation 
procedure by country, discrimination and calibration were 
adequate (pooled C-statistic 0.85 (95% CI 0.81 to 0.88) 
for the full model and 0.84 (95% CI 0.80 to 0.88) for the 
simple model).
Conclusion This prognostic model can identify trauma 
patients at risk of death due to bleeding in a wide range 
of settings and can support prehospital triage and trauma 
audit, including audit of tranexamic acid use.
IntrODuCtIOn
Traumatic haemorrhage is responsible 
for about 2 million deaths each year and 
is a leading cause of preventable death in 
trauma.1–3 Early administration of tranexamic 
acid given within 3 hours of injury reduces 
death due to bleeding by about one-third.4 
Tranexamic acid is widely included in trauma 
care guidelines.5 6 
Nevertheless, many trauma patients who 
might benefit from tranexamic acid are not 
treated or are not treated soon enough.7 
Despite an increase in tranexamic acid use 
after regionalisation of trauma services in 
England, 42% of bleeding trauma patients did 
not receive it.8 There are many ways to increase 
adherence to guidelines, ranging from educa-
tion to financial incentives and regulation.9 
Audit and feedback are particularly effective 
and have helped increase the timely use of 
reperfusion therapies in patients with myocar-
dial infarction and stroke.10–13 Audit and feed-
back are also important in trauma care.14–16 
Prognostic models estimate the risk of death 
for each patient and allow us to target the 
population to audit. We can also calculate a 
clinical score that can be used for initial triage. 
To allow the audit of tranexamic acid use in 
trauma patients, we developed and validated a 
prognostic model to predict the risk of death 
due to bleeding based on information available 
at the first clinical assessment.
MethODs
study population
We used data from two large multicentre 
studies to develop a widely applicable 
strengths and limitations of this study
 ► While there are models that predict all-cause mor-
tality for trauma, this prognostic model is the first to 
identify trauma patients from a wide range of set-
tings at risk of death due to bleeding.
 ► We used a rigorous innovative method to develop 
and validate this prognostic model with an inter-
nal–external cross-validation method based on data 
from 41 countries to ensure that the result is widely 
applicable.
 ► This model can support clinical decision-making for 
prehospital triage and for identifying population to 
audit to help implementation of effective interven-
tion such as tranexamic acid.
 ► As the objective of this model was to identify 
the population at risk of death due to bleeding, dis-
crimination showed a good ability and homogenous 
results across countries.
 ► Due to narrow range in the case-mix of some coun-
tries, we observed statistical heterogeneity in terms 
of calibration.
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prognostic model for death due to bleeding in trauma 
patients: an international randomised control trial (The 
Clinical Randomisation of Anti-fibrinolytic in Significant 
Haemorrhage [CRASH-2] trial) and the Northern French 
Alps Trauma registry.17 18
The CRASH-2 trial included patients from 274 hospi-
tals in 40 countries from 2005 to 2010. Patients with or at 
risk of significant bleeding within 8 hours of injury were 
included. Since tranexamic acid is effective only within 
3 hours of injury, we excluded patients treated beyond 
3 hours.
The Northern French Alps trauma registry, part of 
the Northern French Alps trauma system (TRENAU), 
includes 24 hospitals and 16 prehospital mobile inten-
sive care units from 3 emergency medical service systems. 
Patients, from 2009 to2016, with major trauma according 
to the triage rules of the American College of Surgeons 
were included.19 We excluded patients with cardiac arrest 
at the scene of the injury.
Outcome and variable selection
The primary outcome was in-hospital death due to 
bleeding within 28 days. In the CRASH-2 trial, the clini-
cian responsible recorded the cause of death. In the 
Northern French Alps registry, two trauma surgeons and 
two emergency physicians reviewed the records of all 
patients who died to determine the cause of death. We 
selected potential predictors from the CRASH-2 trial data 
collected before randomisation. We focused on the data 
available in the prehospital setting or on hospital admis-
sion in the Northern French Alps Trauma registry. These 
data included demographic characteristics (age, sex), 
physiological parameters (systolic blood pressure (SBP), 
heart rate (HR), respiratory rate (RR), Glasgow coma 
scale (GCS)) and the mechanism of injury (blunt or pene-
trating). All variables could be assessed at the first clinical 
assessment and were available in hospital records. Phys-
iological variables were the first measures recorded. We 
also included treatment by tranexamic acid and country 
income level (high, middle or low income). Treatment 
by tranexamic acid was included in the equation for 
statistical adjustment. The coefficient for tranexamic 
acid treatment was constrained in the model equation to 
obtain a prediction before treatment at the first clinical 
assessment. Therefore, we used the entire dataset and not 
just the placebo arm of the CRASH-2 randomised trial. 
We assessed the importance of each predictor with the 
partial R2 statistic that estimates the variability of the 
outcome explained by the predictor. We developed two 
models. A full model that included all potential predic-
tors and a simple model.
Model development
We used multivariable logistic regression with random 
effects by country to identify predictors of death due to 
bleeding. Continuous variables were included in the model 
as linear terms. We assessed departures from linearity by 
plotting the risk of death against continuous variables 
and added quadratic and cubic terms to the model for all 
continuous variables that showed a non-linear relation-
ship graphically. The GCS was used as a continuous vari-
able. We used a backward stepwise method by including 
all variables, quadratic and cubic terms and plausible 
interactions between the mechanism of injury and SBP, 
between the mechanism of injury and GCS, and between 
age and SBP. We then removed, one at a time, variables for 
which there was no evidence of association (p>0.05) from 
the Wald test. We also used the Least Absolute Shrinkage 
and Selecting Operator (LASSO) method to check that 
variable selection obtained by the ordinary least squares 
method was similar.20
Model performance
We assessed the model performance in terms of discrim-
ination and calibration. Discrimination was assessed with 
the C-statistic and the receiving operating character-
istic curve.21 Calibration was assessed as the difference 
between mean observed and predicted probabilities (cali-
bration in the large) and by plotting observed outcome 
and predicted probabilities by decile of the predicted risk 
of death and with a non-parametric smooth function.22 
We estimated the calibration slope based on the linear 
predictor of each model. A calibration slope of 1 and an 
intercept of 0 indicates perfect calibration. The overall 
calibration was summarised by the ratio of expected and 
observed number of events (E/O) with an ideal value of 
1.23 A value <1 indicates an underprediction and a value > 
1 indicates an overprediction.
Model validation
We performed internal validation to estimate the statistical 
optimism of the final model. We drew 200 bootstrapped 
samples of 23 402 patients. We developed a model in 
each bootstrapped sample including variable selection. 
We estimated the C-statistic in each bootstrapped sample 
and assessed the performance of each model in the orig-
inal sample. Optimism was estimated as the mean of the 
difference between the C-statistic of the bootstrap sample 
and the C-statistic in the original sample. We subtracted 
optimism from the C-statistic of the model developed 
in the original sample to obtain the optimism-corrected 
C-statistic.
We also conducted an internal–external validation.24–26 
We performed a cross-validation procedure where we 
selected countries with a sample size > 300.25 27 We left 
out one country in turn and developed models using 
the same predictors in the remaining countries and esti-
mated the discrimination and calibration in the omitted 
country. C-statistics, calibration slope and overall calibra-
tion for each country were pooled with random effects. 
We assessed heterogeneity with I2 statistics and by testing 
interaction between calibration slope and country.
Missing data
There was no loss to follow-up in the CRASH-2 trial 
and <0.3% in the Northern French Alps Trauma registry. 
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There were 0% to 2% missing values for predictors in 
the CRASH-2 trial and 0% to 5% in the Northern French 
Alps Trauma registry. We performed multiple imputa-
tion by chained equations to fill in the missing values 
of predictors.28 We generated 20 imputed datasets. We 
imputed 2253 missing values (1.6%) for 1317 incomplete 
observations.
Patient and public involvement statement
Patients were not involved in the research question and in 
the design of the study.
All analyses were performed using STATA software 
V.14.0; and R software V.3.4.3 (R foundation for statistical 
computing).
results
We included 23 430 trauma patients in the study (13 485 
in the CRASH-2 trial and 9945 in the Northern French 
Alps registry, tables 1 and 2). In both the CRASH-2 
and Northern French Alps cohorts, the patients were 
mostly men with a median age of 30 and 35 years respec-
tively. Patients who died from bleeding had lower SBP, 
lower GCS scores and higher HRs. Penetrating injury was 
more frequent in the CRASH-2 trial patients (51%) than 
in the Northern French Alps (5%). Eight hundred and 
fifteen patients (6%) died from bleeding in the CRASH-2 
trial and 102 (1%) in the Northern French Alps cohorts 
(table 3). Half of the Northern French Alps patients had 
Table 1 Characteristics of the CRASH-2 trial  patients
Missing (%)
All patients 
n=13 485
Alive
n=11 404
All causes of death 
n=2081
Death due to 
bleeding n=815
Age, median (IQR) 0 30 (24–42) 30 (23–41) 34 (25–46) 32 (25–45)
SBP, median (IQR) 2 90 (80–110) 95 (80–110) 80 (70–100) 77 (60–90)
HR, median (IQR) 1 106 (92–120) 105 (90–120) 112 (98–128) 116 (100–130)
RR, median (IQR) 1 22 (20–26) 22 (20–26) 24 (20–30) 24 (20–30)
GCS, n (%) 0
  3–8 2125 (16%) 1030 (9%) 1094 (53%) 360 (35%)
  9–12 1784 (13%) 1451 (13%) 332 (16%) 171 (21%)
  13–15 9578 (71%) 8918 (78%) 654 (31%) 360 (44%)
Penetrating Injury, n (%) 0 6874 (51%) 5958 (52%) 916 (44%) 485 (60%)
CRASH-2, Clinical Randomisation of Anti-fibrinolytic in Significant Haemorrhage; GCS, Glasgow  Coma Scale; HR, heart rate (bpm); RR, 
respiratory rate (bpm); SBP, systolic blood pressure (mm Hg).
Table 2 Characteristics of the Northern French Alps registry
Missing (%) All patients n=9945 Alive n=9256
All causes of 
death n=661
Death due to 
bleeding n=102
Age, median (IQR) <1 36 (22–53) 35 (22–51) 58 (31–73) 51 (31–68)
SBP, median (IQR) 3 124 (110–140) 125 (111–140) 116 (80–140) 83 (60–110)
HR, median (IQR) 4 84 (74–100) 85 (75–100) 84 (60–110) 97 (60–120)
RR, median (IQR) 4 16 (15–20) 16 [15-–20] 15 (14–20) 17 (11–25)
GCS, n (%) 3
  3–8 1170 (12) 718 (8) 449 (70) 51 (52)
  9–12 500 (5) 452 (5) 48 (7) 10 (10)
  13–15 7984 (83) 7813 (87) 148 (23) 37 (38)
Penetrating injury <1 554 (6) 508 (6) 45 (7) 16 (16)
Injury severity Score, n 
(%)
2
  0–8 2738 (28) 2723 (30) 14 (2) 1 (1)
  9–15 2480 (26) 2450 (27) 26 (4) 6 (6)
  16–24 2081 (21) 2008 (22) 68 (11) 15 (15)
  25–34 1778 (18) 1453 (16) 316 (49) 36 (36)
  >35 686 (7) 465 (5) 221 (34) 41 (41)
 GCS, Glasgow Coma Scale; HR, heart rate (bpm); RR, respiratory rate (bpm);  SBP, systolic blood pressure (mm Hg).
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an Injury Severity Score (ISS) of 16 or more and three 
quarters had an ISS of 9 or more.
Figure 1 shows the relationships between the potential 
predictors and death due to bleeding. The risk of death 
due to bleeding was higher with higher age, lower SBP 
and lower GCS. HR and RR showed U-shaped relations. 
The predictors included in the full model were age, SBP, 
GCS, HR, RR and the mechanism of injury. Sex and 
country income were not associated with death due to 
bleeding in multivariable analysis (online supplemen-
tary 1 and 2). The LASSO method gave similar results. 
Age, SBP and GCS had the strongest prognostic value 
according to partial R2. The performance of the model 
development showed good discrimination with C-statis-
tics of 0.88 (0.87 to 0.89) and 0.87 (0.86 to 0.88) for the 
full and simple models respectively (table 4). Calibra-
tion was good with no differences between observed and 
predicted deaths due to bleeding, except for high-risk 
Table 3 Risk of death and intervention
CRASH-2
n (%)
Northern French 
Alps Trauma 
registry n (%)
Death due to bleeding 815 (6) 102 (1)
Overall death 2081 (15) 661 (7)
Admission in ICU 5354 (40) 4205 (42)
Surgical procedure 6608 (49) 2691 (27)
Surgical procedure for 
bleeding
916 (7) 1251 (12)*
Blood transfusion, 6506 (48) 1054 (11)
ICU median day (IQR) 3 (1–7) 4 (2–10)
*including embolisation
CRASH-2, Clinical Randomisation of Anti-fibrinolytic in Significant 
Haemorrhage;  ICU, intensive care unit.
Figure 1 Relationship between death due to bleeding and potential predictors.
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patients (n=138) in whom the risk was over-estimated 
above a predicted probability of 0.5 (figure 2). Bootstrap 
resampling showed negligible model optimism of 0.0023 
and gave an optimism-corrected performance that was 
unchanged with a C-statistic of 0.88 and 0.87 for the full 
and simple models. At internal–external cross-validation, 
the C-statistic ranged from 0.80 to 0.94, except for India 
with a C-statistic of 0.72 (figure 3). The pooled C-statis-
tics were 0.85 (0.81 to 0.88) and 0.84 (0.80 to 0.88) for 
the full and simple models respectively (table 4). Pooled 
calibration slope was 1.07 (0.91 to 1.24) and 1.12 (0.95 
to 1.29). Calibration slope and overall calibration showed 
heterogeneity, especially for Iraq, Georgia and Indonesia 
(figures 4 and 5). We found a significant interaction 
between calibration slope and country (p<0.001).
DIsCussIOn
Main findings
We developed and internationally validated a prog-
nostic model to predict death due to bleeding in trauma 
patients. The model showed good discrimination and 
calibration in a wide range of settings. By using clinical 
parameters that can be assessed at the site of injury and 
available in hospital records, we can accurately estimate 
the risk of death due to bleeding in a population with 
major trauma.
strengths AnD lIMItAtIOns
This study has several strengths. We used data from 
well-described inception cohorts of bleeding trauma 
Table 4 Model performance, internal and internal–external validation. 
Full model Simple model
Development
Internal–external 
validation* Development
Internal–external 
validation*
n=23 402 n=22 422 n=23 402 n=22 422
C- statistic (AUC) 0.88 (0.87–0.89) 0.85 (0.81–0.88) 0.87 (0.86–0.88) 0.84 (0.80–0.88)
Calibration-in-the-large† <0.1 <0.1 <0.1 0.3 (0.1–0.6)
Calibration slope 1.01 (0.96–1.07) 1.07 (0.91–1.14) 1.04 (0.98–1.09) 1.12 (0.95–1.29)
E/O 1.02 (0.96–1.08) 0.93 (0.71–1.15) 0.98 (0.92–1.04) 0.91 (0.82–0.99)
*Internal–external validation based on pooled data with random effect obtained by cross validation from 13 countries (each with n≥300). Every 
country is left out once for validation of a model based on the remaining countries.
†Calibration-in-the-large showed difference between observed and predicted death due to bleeding.
AUC, area under the curve (C-statistic); E/O: expected/observed number of deaths due to bleeding.
Figure 2 Calibration curves for model development. AUC, area under the curve.
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Figure 3 Internal–external cross-validation C-statistics by countries. AUC, area under the curve.
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Figure 4 Internal–external cross-validation of calibration slope by countries.
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Figure 5 Internal–external cross-validation overall calibration expected and observed number of  deaths due to bleeding (E/O) 
by countries.
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patients with or at risk of significant haemorrhage. Prog-
nostic factors collected correspond to the first measure 
recorded after injury. Unlike previous studies, loss to 
follow-up was minimal.29 We used a well-defined outcome 
at a fixed time point after injury. These strengths help 
ensure the internal validity of the model.
We developed our model in a large international 
cohort with patients from 40 countries and a large trauma 
registry. This helps to ensure that our results are widely 
applicable. We did not split the data randomly or use 
separate derivation and validation cohorts. Because the 
number of outcome events is the limiting factor in prog-
nostic studies, we used the full dataset with more than 
900 traumatic deaths due to bleeding to ensure accurate 
prediction and strengthen internal validity. Splitting the 
data could have led to a pessimistic and unstable estimate 
of performance.30 For this reason, we did not perform 
split-sample validation and preferred to perform inter-
nal-external cross-validation that has been recommended 
for assessing generalisability.24 We also performed 
boostraping that helps to estimate the model optimism. 
However, we welcome further external validation in 
different trauma cohorts by different authors.31
Our study also has limitations. We cannot rule out 
misclassification of the outcome. The cause of death 
can be difficult to determine, especially in late bleeding 
deaths that could be confused with thrombotic dissem-
inated intravascular coagulation (DIC).6 If deaths due 
to DIC were misclassified as deaths due to bleeding, this 
might underestimate the effect of SBP, HR or RR in this 
model.
Another limitation was the potential for measurement 
error in prognostic factors. The use of a single measure-
ment for blood pressure rather than the average of several 
measurements could lead to error and regression dilution 
bias.32 The regression line between outcome and predictor 
is fitted in order to minimise the distance between each 
point and the line. The random error of the predictor 
increases the distance to the regression line and under-
estimates the effect of the predictor by flattening the 
regression line.33 This may explain the over-prediction 
in high risk patients. Patients with haemorrhagic shock 
and haemodynamic instability are more likely to have 
blood pressure variation and, hence, measurement error. 
This over-prediction occurred  only for trauma patients 
with a very high predicted risk of death due to bleeding 
(above 0.45), representing <0.6% of the study population 
(n=138). In these very high-risk patients, precise quantifi-
cation of the risk of death is unlikely to influence clinical 
decisions. On the other hand, accurate prediction is clini-
cally important in low-risk patients, as, for example, it may 
determine who receives tranexamic acid.
Finally, we observed heterogeneity of performance 
across countries. We note that the discriminative ability is 
affected by miscalibration and case-mix.26 The relatively 
poor C-statistic in India could be explained by the combi-
nation of calibration slope below 1 and a relatively homog-
enous case-mix. On the other hand, the high C-statistic in 
France reflected that the Northern French Alps trauma 
registry selected a more heterogeneous case-mix popula-
tion with major trauma. We acknowledge that this model 
is suitable for a population similar to that used in this 
study, such as a population with major trauma.
Implications of study
Our prognostic model provides a way of identifying 
trauma patients with or at risk of significant haemor-
rhage based on predicted probabilities of death due to 
bleeding. Quality improvement programmes could use 
this model to estimate the individual risks of death due to 
bleeding in a trauma population. Based on these predic-
tions, a trauma audit could determine a threshold for 
patients with ‘significant haemorrhage’ who should be 
treated with tranexamic acid. The threshold used may 
depend on effectiveness, cost and safety considerations. 
According to European guidelines for the management 
of traumatic bleeding, tranexamic acid is supported by 
the highest level of evidence (grade 1A).5 Tranexamic 
acid costs about one pound per patient and has no serious 
adverse effects. For these reasons, a low predicted risk of 
bleeding death might be used in trauma audit.
An internet application has been prepared using our 
simple model for use in the prehospital setting ( www. 
evidencio. com). This could help paramedics decide who 
should receive tranexamic acid at the scene of injury. It 
could also be useful in prehospital triage. Some previ-
ously proposed trauma scores predict all-cause mortality 
or massive transfusion.29 34 35 Ours is the only model that 
predicts death due to bleeding. Because bleeding is the 
leading cause of preventable death, the model might 
become an essential tool for identifying patients needing 
urgent interventions such as damage control surgery and 
multispeciality critical care. It could also help identify 
patients who need to be transported directly to a regional 
trauma centre or for whom massive transfusion protocol 
needs to be activated before they arrive at the hospital.
A prognostic model predicting all-cause mortality was 
developed previously using CRASH-2 data.36 However, 
traumatic deaths can result from many different patho-
physiological mechanisms. For example, both high and 
low SBP predict death from all causes but only low blood 
pressure predicts death due to bleeding. The association 
of high blood pressure with all-cause mortality is likely to 
reflect deaths from traumatic brain injury. By combining 
different mechanisms of death, predictions based on 
all-cause mortality could misclassify the risk of death from 
bleeding.
Future stuDIes
Our models may facilitate stratification of clinical trial 
populations into risk categories at baseline. Future 
studies may examine if and how the effect of tranexamic 
acid varies with baseline risk and model the health impact 
of different treatment strategies.
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